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of amputation. In clinical studies the effectiveness of Hy-
perbaric oxygene therapy of diabetic foot lesion was
proved. Hyperbaric oxygene therapy adjunctive to ther-
apy of diabetic food lesion can reduce anaerobic infec-
tions, improve blood supply and decrease ischemic dam-
age to nerves.
OBJECTIVE: This analysis centred around which of the
alternative therapies-standard therapy plus Hyperbaric
oxygene therapy and standard therapy alone-incurs the
best cost-effectiveness ratio. The comparison of costs and
benefits was made on the basis of a cost-effectiveness
analysis.
METHODS: A decision tree with four endpoints was
constructed: (1) successful therapy without amputations,
(2) small amputations, (3) major amputations with post
hospital treatment, and (4) major amputation with do-
mestic nursing. Data regarding the number and severity
of amputations underlying were taken from a clinical
study. Health care costs included in the model were all
medical costs (hospitalisation, surgical intervention, drug
costs, etc.) and indirect costs (absence from workplace,
retirement). The effectiveness was defined as avoided ma-
jor amputation. The following effectiveness rates were re-
vealed in the clinical study: population with adjunctive
Hyperbaric oxygene therapy, 0.9143; population only
with standard therapy, 0.6666. To improve the robust-
ness of the model, a sensitivity analysis was performed to
determine the influence of the efficacy on the incremental
cost-effectiveness ratio and the effects of of the costs of
post hospital treatment based on the incremental cost-
effectiveness ratio.
RESULTS: Standard therapy plus hyperbaric oxygene
therapy resulted in total costs of DM 45,141.00 per suc-
cessfully treated patient; standard therapy incurred total
costs of DM 52,392.00 per successfully treated patient.
CONCLUSION: The decision tree analysis reveals that
the treatment of diabetic foot lesion with adjunctive Hy-
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An estimated 8 million people in the U.S. have type II dia-
betes mellitus but are unaware of it.
OBJECTIVES: The study investigated the cost-effective-
ness of early detection of type II diabetes mellitus in vari-
ous risk groups.
METHODS: A Markov model was constructed based on
a societal perspective. There were 4 stages in the model:
(1) unknown diabetes status; (2) alive with diagnosed di-
abetes; (3) alive with diagnosed diabetes and related com-
plications, namely, retinopathy, blindness, neuropathy,
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end-state renal disease, lower leg amputations, circula-
tory disorders; and (4) die secondary to diabetes or its
complications. Individuals could transit from one state to
another annually as a function of the predicted risk fac-
tors from epidemiological studies. The model assumed
that the patients who were screened positive for diabetes
and received treatment would have reduced rate of re-
lated complications as observed in the Diabetes Control
and Complications Trial. Health care costs included in
the model were screening tests, diabetes treatment cost,
complications and death. Various screening test thresh-
olds have also been considered in the model analysis.
RESULTS: Diabetes screening of the entire nonpregnant
adult US population yielded a cost-effectiveness ratio of
$24,600 per quality-adjusted life year. The cost-effective-
ness of screening only extremely obese patients with a
family history of diabetes was $10,083 per quality-
adjusted life year.
CONCLUSIONS: The study suggested that active screen-
ing for type II diabetes mellitus in high-risk individuals
was cost-effective. More information on the actual clini-
cal outcomes for oral diabetes medications is needed to
establish the precision of these estimates.
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OBJECTIVE: The main objectives of this paper were to
develop and subsequently test a Bayesian discrimination
model for the purpose of identifying both the personal
and the health care system characteristics predictive of
hospitalization for the treatment of diabetes or commonly
observed comorbidities associated with the disease,
METHODS: First, a Bayesian classification framework
was proposed to discriminate patients into two groups-
the high risk and the low risk. The model was then tested
by using a logit regression technique in order to estimate
the probability of one or more hospitalization events
among diabetes patients. The study used claims data ex-
tracted from the Hawaii Medical Service Association
(HMSA) Private Business Claims (PBS) files for the calen-
dar year 1995. Patients under 65 years were identified by
paid claims with ICD-9-CM diagnosis codes of 250.xx
which gave a sample size of 6,841.
RESULTS: Age, gender, various pharmacotherapy vari-
ables, presence of hypertension, hyperlipidemia, coronary
heart failure, multiple cardiovascular diseases, any com-
bination of commonly observed comorbidities, dialysis
services, and annual eye examination were highly predic-
tive of one or more hospitalization events. The model
showed a predictive power of almost 90%.
CONCLUSION: Multivariate discriminant analysis using a
logit regression model successfully (1) identified important
explanatory variables predictive of hospitalization, (2) as-
